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The objective of this study was to perform a meta-analysis of randomized controlled trials (RCTs) investigating
whether a remote ischemic preconditioning (RIPC) protocol provides renal protection to patients undergoing
cardiac and vascular interventions. Searches were conducted in the databases PUBMED, EMBASE and Cochrane
Library. RCTs that fulfilled the inclusion criteria and addressed the clinical questions of this analysis were further
assessed. We identified ten studies with a total of 924 patients undergoing cardiac and vascular interventions with
or without RIPC. There was a significantly lower incidence of acute kidney injury in the RIPC group compared with
control group using the fixed effect model (RR 0.69, 95% CI 0.53 to 0.90, P = 0.007), but not with the random
effects model (RR 0.73, 95% CI 0.50 to 1.06, P = 0.10). There was no difference in the levels of renal biomarkers,
incidence of renal replacement therapy, mortality, hospital stay, and intensive care unit stay between two groups. In
conclusion, there is no enough evidence that RIPC provided renal protection in patients undergoing cardiac and
vascular interventions. Large-scale RCTs are necessary to confirm the potential role of RIPC on renal impairment.
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Acute kidney injury (AKI) affects up to 45% of patients
undergoing cardiac surgery, percutaneous coronary
intervention, and vascular surgery, and requires postop-
erative renal replacement therapy in nearly 1 to 2% [1,2].
Patients who develop AKI following cardiac and vascular
interventions continue to have increased morbidity and
mortality and prolonged stays in intensive care unit
(ICU) and hospital [3,4].
Several different injury pathways including exogenous
and endogenous toxins, metabolic and neurohormonal
factors, renal ischemia and inflammatory surgical re-
sponse contribute to the development of AKI during
cardiac and vascular interventions [5-7].
Numerous clinical trials of pharmacologic interventions
have been used to prevent AKI in patients following* Correspondence: youmingli_zju@yeah.net
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reproduction in any medium, provided the orcardiac and vascular surgery; however, these studies have
also been a disappointment [8-10].
Remote ischemic preconditioning (RIPC) is a phenomenon
in which a brief ischemia and reperfusion in distant tissues
protects a critical target organ or tissue from a subsequent
episode of lethal ischemia and reperfusion through either
neuronal or humoral pathway [11-13]. Although the kidneys
are not directly exposed to ischemia-reperfusion injury, RIPC
might preserve kidney function in patients undergoing car-
diac and vascular interventions through blocking free radical
production and attenuating the inflammatory response in-
volved in pathogenesis of AKI [6,7,14]. This technique of
RIPC has significant potential to decrease ischemic injury of
other organs in patients undergoing cardiac and vascular
interventions.
The studies regarding the protective effect of RIPC
against AKI in patients undergoing cardiac and vascular
interventions were limited, and the results remained con-
troversial and contradictory. Therefore, we performed a
meta-analysis to investigate whether a RIPC protocolhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Studies were accepted based on the following criteria:
study design – randomized controlled trial (RCT); study
population – adults who underwent cardiac and vascular
interventions; intervention – RIPC (irrespective of the
duration, timing, and the vessel occluded to provide the
ischemic preconditioning stimulus); comparison inter-
vention – usual treatment without RIPC; primary out-
comes – development of AKI, initiation of renal
replacement therapy, renal biomarkers; secondary out-
comes – mortality, hospital stay, ICU stay. We excluded
review articles, retrospective analyses, case reports as
well as studies that were only reported as abstracts. If
any of data were insufficient or missing, we contacted
the authors to obtain information about missing data.
This study was carried out in strict accordance with the
Helsinki Declaration. The protocol was approved by the
medical ethics committee of the first affiliated hospital
of Zhejiang University (Permit Number: 2012-183).
Literature search
Two investigators independently identified the published
RCT from the PubMed (US National Library of Medi-
cine, Bethesda, MD, USA) (1980 to present), EMBASE
(Reed Elsevier PLC, Amsterdam, The Netherlands)
(1980 to present) and Cochrane Library databases. In
addition, we scanned the bibliographies of all relevant
studies and recent review articles for further potential
references. We also searched for unpublished and on-
going trials in clinicaltrials.gov and controlled-trials.com.
The search terms were “ischemic preconditioning”Figure 1 Identification of trials for inclusion.(subject heading); “cardiovascular surgical procedures”
(subject heading); “randomized controlled trial” (publica-
tion type); “controlled clinical trial” (publication type); “re-
mote ischemic preconditioning” (text keywords) and
“randomized controlled trial” (text keywords). No lan-
guage restrictions were applied to any search strategies.
There was complete consensus among two investigators
on the final results.
Data extraction
Data extraction was performed by two independent ob-
servers using standardized forms. Recorded data in-
cluded the demographic characteristics of the patients,
procedures of operation, protocol for RIPC, the incidence
of AKI, the incidence of hemodialysis or hemofiltration,
mortality, ICU and hospital stays, serum creatinine levels
before and after surgery, glomerular filtration rate (GFR)
before and after surgery. The studies included in the
meta-analysis were assessed for methodological quality
using the Jadad composite scale. According to this scale, a
low-quality study should score 2 or less points and high-
quality study should score 3 or more points [15]. Alloca-
tion concealment was assessed with the classification of
the Cochrane Collaboration. Disagreements were resolved
by contacting authors or reaching a consensus.
Statistical analysis
If several trials were available for a specific topic, meta-
analysis was conducted using the software RevMan 5.1
(provided by the Cochrane Collaboration, Oxford, UK).
We calculated the risk ratio (RR) with 95% confidence
interval for dichotomous outcomes and mean difference
(MD) with 95% confidence interval for continuous out-
comes. We assessed statistical heterogeneity using the χ2
tests and determined the percentage of total variation
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effect model and the random-effects model were used to
pool studies. In case of discrepancy between the two
models we reported both results; otherwise we reported
only the results from the fixed effect model.
Results
Literature search
The search strategy generated 451 studies. After exclu-
sion of 295 duplicates and 133 clearly irrelevant papers
through reading abstracts, 23 papers were retrieved for
further assessment. Of the 23 references, 13 were ex-
cluded because of retrospective analysis of 2 prior studies








Ali et al. [16] 41/41 74/75 93/93 21/26
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DM, diabetes mellitus; PCI, percutaneous coronary intervention; CABG, coronary arteno target outcomes (n = 7). Finally, a total of ten papers
were eligible for this meta-analysis [16-25] (Figure 1).Study characteristics
A total of 924 participants were enrolled in the ten stud-
ies, including six studies in patients undergoing cardiac
surgery, one studies in percutaneous coronary interven-
tion, and three studies in vascular surgery. 464 patients
were randomised to the RIPC group, and 460 to the
control group. There were no significant differences be-
tween two groups with regard to age, sex and preopera-
tive renal status. The important characteristics of the
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The quality of the included studies was assessed using
the Jadad score and allocation concealment classification
of the Cochrane Collaboration. Eight of ten trials had
high methodological quality and a low risk of bias
[16-21,24,25]. The generation of a randomization list
was adequate in eight trials [16-21,24,25]. The allocation
concealment was adequate in eight trials [16-20,23-25].
Double blinding was performed in two trials [20,25].
All trials had a clear explanation for withdrawals and
dropouts in each group. Six trials reported no with-
drawals after randomization [16,18,20,21,24,25]; in four
trials [17,19,22,23], 11.62% (48/413) of patients were
withdrawn after randomization. Only one patient was
lost to follow-up [17] (Table 2).
Effects of interventions
Incidence of acute kidney injury
Information on the incidence of AKI was available for
eight trials included in the meta-analysis [16-21,23,25].
There was a significantly lower risk of AKI in the RIPC
group compared with control group using the fixed ef-
fect model (RR 0.69, 95% CI 0.53 to 0.90, P = 0.007,
Figure 2a), but not with the random effects model (RR
0.73, 95% CI 0.50 to 1.06, P = 0.10, Figure 2b). However,
these findings should be regarded with caution since we
used the definition of AKI applied by the investigators of
the respective studies. The definitions included AKINTable 2 Methodological quality of trials included in meta-ana
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Yescriterion [21,23], RIFLE criterion [25], peak serum cre-
atinine level > 2 mg/dl [16], a postoperative decline in
eGFR > 20% [18,19], and a postoperative rise in serum
creatinine > 0.5 mg/dL [20]. There was a significant het-
erogeneity, with I2 of 44%. Futhermore we performed a
subgroup analysis of the trials with AKIN criterion to
evaluate the efficacy of RIPC for AKI. We observed that
RIPC significantly reduced the risk of AKI with the fixed
effect model (RR 0.65, 95% CI 0.43 to 0.98, P = 0.04),
but not with the random effects model (RR 0.70, 95% CI
0.26 to 1.88, P = 0.48). Large-scale trials are necessary to
investigate the potential effect of RIPC against AKI.Biomarkers of kidney injury
Available information on the data of serum creatinine
for four trials was included in the meta-analysis
[18,19,21,24]. The serum creatinine levels on the first
postoperative day did not differ significantly between
two groups (MD 6.65, 95% CI −1.25 to 14.55, P = 0.10,
Figure 3a). Moreover, there was no significant difference
in serum creatinine levels on the second postoperative
day (MD 1.05, 95% CI −7.05 to 9.14, P = 0.80,
Figure 3b).
Three trials collected the GFR values from the RIPC
and control groups [18,19,21]. There was no difference in
the GFR values between two groups on the first postoper-




































Figure 2 Meta-analysis of relative risk for the incidence of AKI. (a) Fixed effect model; (b) Random effect model.
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95% CI −1.22 to 9.28, P = 0.13, Figure 3d).
Renal replacement therapy
Eight trials evaluated renal replacement therapy as an out-
come [16,18-24]. In six of the eight trials, none of patients
required postoperative hemodialysis or hemofiltration.
Two trials by Walsh et al. [19] and Rahman et al. [20]
reported 6 patients who received renal replacement ther-
apy (5 in the RIPC group and 1 in the control group). No
significant difference was observed in the incidence of
renal replacement therapy between two groups (RR 3.45,
95% CI 0.58 to 20.65, P = 0.17, Figure 4).
Mortality
The mortality was reported in nine trials [16-20,22-25].
There was no statistically significant difference in the
overall mortality between two groups (RR 1.10, 95% CI
0.49 to 2.97, P = 0.68, Figure 5).
Hospital stay
Available information on the hospital stay for three
trials was included in the meta-analysis [20-22]. Nostatistically significant difference was observed in the
hospital stay between two groups (MD 0.07, 95% CI
−0.50 to 0.64, P = 0.81, Figure 6).ICU stay
Information on the time of ICU stay for two trials was
included in the meta-analysis [21,22]. There was no sta-
tistically significant difference in the ICU stay between
two groups (MD −0.14, 95% CI −0.35 to 0.08, P = 0.23,
Figure 7).Subgroup analysis
We performed the subgroup analysis for the patients
undergoing cardiac surgery [17,20-25]. The RR for the
incidence of AKI, hemodialysis requirement and mortal-
ity remained statistically stable. Moreover, a subgroup
analysis of trials using tourniquet cuff around the limb
for RIPC did not reveal any change in the incidence of
AKI, hemodialysis requirement and mortality [17,18,20-25].
We did not perform a subgroup analysis of outcomes for
renal biomarkers, hospital stay and ICU stay as few studies
in the subgroup reported these outcomes.
Figure 3 Meta-analysis of mean difference for the levels of renal biomarkers. (a) serum creatinine levels on the first postoperative day;
(b) serum creatinine levels on the second postoperative day; (c) GFR values on the first postoperative day; (d) GFR values on the second
postoperative day.
Figure 4 Meta-analysis of relative risk for the incidence of renal replacement therapy.
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Figure 5 Meta-analysis of relative risk for mortality.
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We performed a meta-analysis of high quality trials
[16-21,24,25] to evaluate the efficacy of RIPC for renal
protection. There was no significant difference between
two groups for incidence of AKI, renal biomarkers,
hemodialysis requirement, or mortality after excluding
the trials with low quality.
Discussion
RIPC prior to cardiac and vascular interventions has pri-
marily been used to ameliorate heart ischemia-reperfusion
injury [26]. The pooled results of these trials indicate a
significant benefit of RIPC for decreasing the levels of
myocardial necrosis markers and the incidence of peri-
operative myocardial infarction [27-31]. To date, whether
RIPC can protect kidney function in patients undergoing
cardiac and vascular interventions is still a controversial
issue. The meta-analyses by D’Ascenzo et al. [29] and
Brevoord et al. [30] which evaluated the effect of RIPC in
the patients undergoing cardiac and vascular interventions
concluded that serum creatinine levels were both not re-
duced by RIPC. Recently Desai et al. [32] published a
meta-analysis including four RCTs of 115 patients under-
going vascular surgery, which showed no difference in the
incidence of renal impairment between RIPC andFigure 6 Meta-analysis of mean difference for hospital stay.controls. However, the meta-analysis by Alreja et al. [31]
showed that RIPC significantly reduced the levels of
serum creatinine in the first few days after cardiac and
vascular interventions. These apparent inconsistencies
may be due to limitations in few numbers of trials, small
sample size and low to moderate methodological quality.
Therefore, a further update of meta-analysis assessing the
role of RIPC on renal protection in patients undergoing
cardiac and vascular interventions should be performed.
Compared with previous meta-analyses, our paper in-
cluded the studies across a broader population over a lon-
ger time frame. Concerning renal end points, previous
meta-analyses extracted either serum creatinine or inci-
dence of AKI, whereas we tried to extract all renal out-
comes from the included trials.
Our data demonstrate that there was a significantly
lower incidence of AKI in the RIPC group by the fixed
effect model, but no difference between two groups by
the random effects model. The result remained un-
changed in all subgroup analysis. In view of the size and
quality of currently published trials, these data were not
able to conclude whether RIPC has any beneficial or
harmful effects on renal protection.
Furthermore, we assessed renal injury with postopera-
tive measurement of serum creatinine. In contrast to our
Figure 7 Meta-analysis of mean difference for ICU stay.
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atinine levels between two groups. Although the most
widely used biomarker for diagnosis of AKI is serum
creatinine, serum creatinine is a late biomarker of AKI
because it is not accurate in the acute care setting but
rather in the steady-state which can take several days to
reach. In addition, volume expansion during cardiopulmo-
nary bypass in patients undergoing cardiac surgery may
result in a fall of serum creatinine despite the presence of
significant renal injury. Therefore, it is recommended that
some potential early biomarkers for AKI also be examined
in the future studies (e.g., interleukin-18, kidney injury
molecule-1 and neutrophil gelatinase-associated lipocalin).
We also assessed GFR values 24 and 48 hours after the
surgery. Still no benefits were seen in patients treated with
RIPC. Likewise, we did not find a significant reduction in
hemodialysis requirement, mortality, hospital stay and
ICU stay in the RIPC group compared with the control
groups.
The studies included in this review had inconsistencies
in the premedication, anesthesia, and surgical proce-
dures. We intended to carry out subgroup analysis by
type of interventions. Due to the limited number of trials
included, only the group of studies in patients undergo-
ing cardiac surgery was large enough to permit a sub-
group analysis. We found that RIPC did not reduce the
incidence of AKI in patients undergoing cardiac surgery.
The hemodialysis requirement and mortality did not dif-
fer between the RIPC and control group. The present
analysis does not support the hypothesis that RIPC pro-
vides kidney protection in patients undergoing cardiac
surgery. We also made an effort to compare different
protocols of RIPC. Although eight of ten studies used
cuff inflation and deflation around the arm or leg for
RIPC, crossclamping of the iliac arteries was used by Ali
et al. [16] and Walsh et al. [19]; which RIPC protocol is
truly the best for myocardial and renal protection is still
uncertain. The results remained statistically stable in a
subgroup analysis for the incidence of AKI, hemodialysis
requirement and mortality after excluding trials using
iliac artery clamping.
The meta-analysis suffers from the following limita-
tions. First, there were only two double-blind trials in-
cluded in our meta-analysis. In the other eight trials,only patients and laboratory investigators were blinded
to randomization, whereas anesthetists and surgeons
were aware of the participants’ group assignment. There-
fore, the outcomes of this meta-analysis could be
influenced by care providers’ awareness of study group
assignment. Second, some of studies included only pa-
tients without diabetes mellitus, which is associated with
a decreased risk of AKI. Therefore, the findings of this
meta-analysis were not applicable to patients with dia-
betes mellitus because of the heterogeneity for study
population. Third, as mentioned above, various defini-
tions have been suggested for postoperative AKI. Al-
though we have tried to account for this heterogeneity
by using a random effects model and performing sub-
group analysis, these data do not yet allow for definitive
conclusions. Moreover, the definition of AKI used in
these trials does not take into account the duration of
serum creatinine elevation. These limitations may ex-
plain the heterogeneity between studies. Therefore, the
result of the meta-analysis should be interpreted with
caution and be regarded as hypothesis generating, rather
than conclusion drawing.Conclusion
RIPC has no beneficial effect on the postoperative occur-
rence of AKI, renal biomarkers, hemodialysis require-
ment, mortality, or hospital and ICU stays during
cardiovascular interventions. There is no evidence that
RIPC provides renal protection in patients undergoing
cardiac and vascular interventions. However, in view of
the inherent limitations of meta-analysis extracted from
currently published RCTs, our data should be regarded
as exploratory with further studies needed in patients
undergoing cardiac and vascular interventions. The fu-
ture clinical studies should be designed to develop opti-
mal RIPC procedures in accordance with operation type
and elucidate the molecular mechanisms of RIPC.Abbreviation
AKI: Acute kidney injury; RCT: Randomized controlled trial; RIPC: Remote
ischemic preconditioning; ICU: Intensive care unit; GFR: Glomerular filtration
rate; RR: Risk ratio; MD: Mean difference; DM: Diabetes mellitus;
PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass graft.
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